Search Results

Lipidor AB announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022.

Lipidor AB announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris.

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderate psoriasis.

Lipidor AB announced that the company’s Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start.

Lipidor AB provides an update on the planned Phase III study of the company’s drug candidate AKP02 for the treatment of psoriasis.

Lipidor AB announced that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration.

Sweden’s innovation authority Vinnova is investing in Lipidor’s subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.

Lipidor AB (“Lipidor” or the “Company”) and its subsidiary Emollivet AB (“Emollivet”) have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor’s patented AKVANO® technology

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries

Lipidor AB announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor’s drug candidate AKP-02.